Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check ...
Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock fell Monday after the U.S. Food and Drug Administration accepted the company’s Biologics License Application (BLA) for INO-3107 but raised concerns tied ...
This was the stock's third consecutive day of losses.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat ...
Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago. These ...
The market expects Inovio Pharmaceuticals (INO) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus ...
The FDA assigned INO-3107 a Prescription Drug User Fee Act (PDUFA) review goal date of October 30, 2026, which is the date by which it intends to take action on the application. The FDA has indicated ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...
Lead asset, VGX-3100, is targeting the huge unmet demand in the cervical cancer market. Inovio Pharmaceuticals is focused on rapidly advancing the VGX-3100 research program. There are multiple ...
The stock's fall snapped a two-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback